Увійти

Готові списки джерел за темами / CAR-T therapy / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: CAR-T therapy.

Статті в журналах з теми "CAR-T therapy"

Автор: Grafiati

Опубліковано: 12 квітня 2025

Оновлено: 26 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "CAR-T therapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Singh, Yuvraj. "Chimeric Antigen Receptors T Cells (CAR T) Therapy." International Journal of Science and Research (IJSR) 13, no. 5 (2024): 1563–66. http://dx.doi.org/10.21275/sr24523173932.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

San Segundo, Lucrecia Yáñez. "CAR-T cell therapy." Medicina Clínica (English Edition) 156, no. 3 (2021): 123–25. http://dx.doi.org/10.1016/j.medcle.2020.05.030.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Neff Newitt, Valerie. "CAR T-Cell Therapy." Oncology Times 39, no. 20 (2017): 1. http://dx.doi.org/10.1097/01.cot.0000526653.15787.41.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Ahmad, Aamir. "CAR-T Cell Therapy." International Journal of Molecular Sciences 21, no. 12 (2020): 4303. http://dx.doi.org/10.3390/ijms21124303.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Jacobson, Caron, Amy Emmert, and Meredith B. Rosenthal. "CAR T-Cell Therapy." JAMA 322, no. 10 (2019): 923. http://dx.doi.org/10.1001/jama.2019.10194.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Kwon, Miji, and Hee Ho Park. "CAR-T Therapy Targeting Solid Tumor." KSBB Journal 35, no. 2 (2020): 95–104. http://dx.doi.org/10.7841/ksbbj.2020.35.2.95.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

L. Penney, Christopher, Boulos Zacharie, and Jean-Simon Duceppe. "Tucaresol-Cyclophosphamide Combination Therapy: Proposal for a Safe, Affordable Alternative to CAR T-Cell Therapy." Journal of Clinical Review & Case Reports 9, no. 12 (2024): 01–04. https://doi.org/10.33140/jcrc.09.12.02.

Повний текст джерела

Анотація:

Chimeric Antigen Receptor (CAR) T-cell therapy is a newer immunotherapeutic process in which genetic engineering is used to incorporate a receptor protein into a patient’s T-cells thereby permitting the modified T-cells to recognize and eradicate tumors. Initially, CAR T-cell therapy was reserved as a last resort when standard cancer treatments failed to provide significant efficacy but subsequently, CAR T-cell therapy is finding use against earlier stage cancers. Since 2017, seven CAR T-cell therapies have attained FDA approval for treatment of hematological cancers. The latest approval, Nove

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Testa, Ugo, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, and Giuseppe Leone. "CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES." Mediterranean Journal of Hematology and Infectious Diseases 16, no. 1 (2024): e2024031. http://dx.doi.org/10.4084/mjhid.2024.031.

Повний текст джерела

Анотація:

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs and multiple myeloma. These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies. However, the success of CAR-T cell therapies in T-cell neoplasms was

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Hosen, Naoki. "2) CAR T Cell Therapy." Nihon Naika Gakkai Zasshi 108, no. 3 (2019): 438–42. http://dx.doi.org/10.2169/naika.108.438.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Thoma, Clemens. "Developing CAR T cell therapy." Nature Reviews Urology 15, no. 3 (2018): 138. http://dx.doi.org/10.1038/nrurol.2018.4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Abbasi, Jennifer. "Relapses After CAR-T Therapy." JAMA 320, no. 18 (2018): 1850. http://dx.doi.org/10.1001/jama.2018.17585.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Abbasi, Jennifer. "Safer CAR T-Cell Therapy." JAMA 321, no. 22 (2019): 2155. http://dx.doi.org/10.1001/jama.2019.7551.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

SAYIN KASAR, Kadriye, and Yasemin YILDIRIM. "Nursing Management in CAR-T Cell Therapy." Turkiye Klinikleri Journal of Nursing Sciences 12, no. 2 (2020): 272–79. http://dx.doi.org/10.5336/nurses.2019-72274.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Heislerová, Marcela. "CAR-T therapy - the role of the pharmacist." Česká a slovenská farmacie 74, no. 2 (2025): 103–7. https://doi.org/10.36290/csf.2025.014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Puchkov, I. A., T. M. Kulinich, E. I. Parfenyuk, et al. "Futures of CAR-T-therapy of solid tumors." Immunologiya 45, no. 6 (2024): 792–805. https://doi.org/10.33029/1816-2134-2024-45-6-792-805.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Park, Hyunmo, Miji Kwon, Kwang Suk Lim, and Hee Ho Park. "Chimeric Antigen Receptor-T cell (CAR-T) Therapy Targeting Hematologic Malignancy." KSBB Journal 35, no. 3 (2020): 183–91. http://dx.doi.org/10.7841/ksbbj.2020.35.3.183.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Mitchell, Emily, and George S. Vassiliou. "T-Cell Cancer after CAR T-Cell Therapy." New England Journal of Medicine 390, no. 22 (2024): 2120–21. http://dx.doi.org/10.1056/nejme2405538.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Dr., Vachaspati Narayan Dr. Mahender Miland Dr. Kritika Gahlot Dr. Mukul Purva. "Chimeric Antigen Receptor T-cell Therapy (CAR T)." Science World a monthly e magazine 2, no. 8 (2022): 1467–71. https://doi.org/10.5281/zenodo.7015559.

Повний текст джерела

Анотація:

This is an adoptive T-cell therapy which uses engineered T-cell. In which they are obtain from a patient’s immune system by its own to attack cancer cells through targeting proteins expressed on the cellular membrane, that process involves obtaining T-cells via a leukapheresis procedure. These cells are sent to a centralized manufacturing facility where they are genetically modified to produce specific chimeric antigen receptors and expanded in a cell culture. This process may take up to few weeks. This product is then returned to the treating facility and re-infused into the patient rec

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Song, Kun-Wei, and Brian J. Scott. "CAR T-cell therapy for gliomas." Current Opinion in Neurology 37, no. 6 (2024): 672–81. http://dx.doi.org/10.1097/wco.0000000000001318.

Повний текст джерела

Анотація:

Purpose of review To review the landscape of chimeric antigen receptor T-cell (CAR T) therapy for gliomas as seen in recently published trials and discuss on-going challenges with new cancer immunotherapy treatments. Recent findings Given how CAR T therapy has revolutionized the treatment of several hematologic malignancies, there has been increasing interest in using immunotherapy, and particularly CAR T therapy for gliomas. Within the past decade, several first in human trials have published early patient experiences showing treatment is generally well tolerated but with limited efficacy, wh

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Uscanga-Palomeque, Ashanti Concepción, Ana Karina Chávez-Escamilla, Cynthia Aracely Alvizo-Báez, et al. "CAR-T Cell Therapy: From the Shop to Cancer Therapy." International Journal of Molecular Sciences 24, no. 21 (2023): 15688. http://dx.doi.org/10.3390/ijms242115688.

Повний текст джерела

Анотація:

Cancer is a worldwide health problem. Nevertheless, new technologies in the immunotherapy field have emerged. Chimeric antigen receptor (CAR) technology is a novel biological form to treat cancer; CAR-T cell genetic engineering has positively revolutionized cancer immunotherapy. In this paper, we review the latest developments in CAR-T in cancer treatment. We present the structure of the different generations and variants of CAR-T cells including TRUCK (T cells redirected for universal cytokine killing. We explain the approaches of the CAR-T cells manufactured ex vivo and in vivo. Moreover, we

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Ren, Anqi, Yuan Zhao, and Haichuan Zhu. "T-ALL Cells as Tool Cells for CAR T Therapy." Vaccines 11, no. 4 (2023): 854. http://dx.doi.org/10.3390/vaccines11040854.

Повний текст джерела

Анотація:

T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic malignancy derived from T cells. Numerous CAR T therapies have been successfully applied to treat hematologic malignancies in the clinic. Nevertheless, there remain several challenges to the extensive application of CAR T cell therapy in T cell malignancies, especially in T-ALL. The main reason for CAR T therapy limitations is that T-ALL cells and normal T cells share antigens, which improves the difficulty of sorting pure T cells, resulting in product contamination, and would lead to CAR T cell fratricide. Thus, we considered creati

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Kato, Junichi, Tatsuya Konishi, Takatsugu Honda, et al. "Bystander CAR⁻CD8⁺T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody." Journal for ImmunoTherapy of Cancer 13, no. 6 (2025): e011690. https://doi.org/10.1136/jitc-2025-011690.

Повний текст джерела

Анотація:

Although bispecific antibody (BsAb) treatment is a valuable therapeutic option for post chimeric antigen receptor (CAR)-T cell therapy against relapsed/refractory large B-cell lymphoma, it remains to be clarified why it is still effective after intensive T-cell redirection therapy. Recently, the therapeutic potential of bystander CD8+T cells in the field of cancer immunotherapy have been discussed. In this study, we have shown a clinical impact where bystander CAR-negative CD8+T cells from a CAR-T cell product have a potential to augment immune responses of BsAb therapy through a case with rel

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Kew, Kayleigh. "What is CAR T-cell therapy?" Drug and Therapeutics Bulletin 59, no. 5 (2021): 73–76. http://dx.doi.org/10.1136/dtb.2020.000040.

Повний текст джерела

Анотація:

The emergence of targeted and precision therapies has increased treatment options for people living with cancer. Of particular note is the development and approval of chimeric antigen receptor (CAR) T-cell therapies that involve the use of a patient’s own immune system to treat cancers that have proven resistant to other approaches. Keeping abreast of treatment changes and practice guidelines is a challenge for all healthcare professionals, and the pressure of doing so becomes most acute with innovations in cancer therapeutics that have the potential to extend or save lives. Though uncommon, s

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Dickson, Iain. "Improved CAR T therapy for PDAC." Nature Reviews Gastroenterology & Hepatology 18, no. 7 (2021): 456. http://dx.doi.org/10.1038/s41575-021-00476-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Kurt, Selver. "CAR-T CELL THERAPY IN CLL." Hematology, Transfusion and Cell Therapy 46 (December 2024): S20. https://doi.org/10.1016/j.htct.2024.11.117.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Pang, Zilong. "CAR T-cell Therapy for GBM." Theoretical and Natural Science 71, no. 1 (2024): 84–90. https://doi.org/10.54254/2753-8818/2024.la18770.

Повний текст джерела

Анотація:

Glioblastoma multiforme (GBM) is the most lethal and common primary malignant brain tumour. It has a 100% mortality rate and poor prognosis, and is currently incurable. Conventional treatments, such as surgery, can only extend patients survival to a very limited extent and are often accompanied by severe side effects. In recent decades, chimeric antigen receptor (CAR) T-cells therapy has emerged as a novel immunotherapy with great potential in treating various tumours, raising high expectations for its application in GBM. This paper reviews the structure and function of CAR design and discusse

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Fan, Mingliang, Jiayu Zheng, Yue Huang, Mingxia Lu, Zhi Shang, and Mingwei Du. "Nanoparticle-mediated universal CAR-T therapy." International Journal of Pharmaceutics 666 (December 2024): 124779. http://dx.doi.org/10.1016/j.ijpharm.2024.124779.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Ramos, Carlos A., Helen E. Heslop, and Malcolm K. Brenner. "CAR-T Cell Therapy for Lymphoma." Annual Review of Medicine 67, no. 1 (2016): 165–83. http://dx.doi.org/10.1146/annurev-med-051914-021702.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Adusumilli, Prasad. "CAR T therapy for solid tumors." Leukemia Research 85 (October 2019): S14. http://dx.doi.org/10.1016/s0145-2126(19)30226-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Schlegel, Patrick. "CAR-T cell therapy in pediatrics." Leukemia Research 85 (October 2019): S16. http://dx.doi.org/10.1016/s0145-2126(19)30234-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Muhammad, Niaz, Qinwen Mao, and Haibin Xia. "CAR T-cells for cancer therapy." Biotechnology and Genetic Engineering Reviews 33, no. 2 (2017): 190–226. http://dx.doi.org/10.1080/02648725.2018.1430465.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Mullard, Asher. "FDA approves first CAR T therapy." Nature Reviews Drug Discovery 16, no. 10 (2017): 669. http://dx.doi.org/10.1038/nrd.2017.196.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

He, Shujun. "CAR T-cell Therapy for Neuroblastoma." Highlights in Science, Engineering and Technology 36 (March 21, 2023): 913–17. http://dx.doi.org/10.54097/hset.v36i.6123.

Повний текст джерела

Анотація:

Children aged under 5 being the main patient group of neuroblastoma has been widely acknowledged according to clinical diagnosis results. Traditional therapies like monoclonal therapy and chemo therapy have achieved relatively high curing rate, the 5-year survival rate of these therapies are still not acceptable, followed by strong side effects to microenvironment. To help improve the prognosis of patients who have high risk and lift the survival rate, CAR T-cell therapy for neuroblastoma can be an achievable option. In this review, I summarize the mechanism of CAR T cell therapy, the general

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Jenkins, Misty R., and Katharine J. Drummond. "CAR T-Cell Therapy for Glioblastoma." New England Journal of Medicine 390, no. 14 (2024): 1329–32. http://dx.doi.org/10.1056/nejme2401307.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Liu, Botao, Lingyun Ma, Jing Xu, and Gege Yan. "CAR-T therapy for breast cancer." Theoretical and Natural Science 20, no. 1 (2023): 184–92. http://dx.doi.org/10.54254/2753-8818/20/20230762.

Повний текст джерела

Анотація:

The most common form of cancer among women is breast cancer. With the increasing negative impact of breast cancer on human life and health, scientists have devoted more detailed research on breast cancer treatment and there has been the discovery of a novel CAR-T cell immunotherapy method. Based on the results of the research on CAR-T therapies for breast cancer, this paper summarizes the targets of the therapy for breast cancer, discusses the challenges faced by the treatment of the cancer, and proposes effective strategies to solve the difficulties and overcome the challenges. So far, studie

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Al-Janabi, Ismail Ibrahim. "CAR-T Cell Therapy for Cancer." Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) 6, no. 2 (2024): 21–31. http://dx.doi.org/10.54133/ajms.v6i2.726.

Повний текст джерела

Анотація:

Objective: To provide a basic overview of the status of CAR-T cell therapy and foresee its future applicability in cancer treatment. Method: The search engines PubMed, Google Scholar, ResearchGate and Web of Science were employed in obtaining peer-reviewed articles using the criteria outlined in the method section. Main points: CAR-T cell therapy has proved a lifesaving option for hematological malignancies despite its huge cost per treatment. Clinical trials are still ongoing to improve the effectiveness of this therapy for solid tumors as well as make it more affordable and easier to set up.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Du, Bing, Juliang Qin, Boxu Lin, Jiqin Zhang, Dali Li, and Mingyao Liu. "CAR-T therapy in solid tumors." Cancer Cell 43, no. 4 (2025): 665–79. https://doi.org/10.1016/j.ccell.2025.03.019.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Patil, Bhavesh* Sayyed A. Kirmani Kawade R. .M. "Car-T Cell Therapy: A Review." International Journal of Pharmaceutical Sciences 2, no. 12 (2024): 441–52. https://doi.org/10.5281/zenodo.14274595.

Повний текст джерела

Анотація:

It has just been determined that cancer is the primary cause of death globally. Numerous traditional remedies as well as cytotoxic immunotherapies have been created and introduced to the market. A promising immunotherapy that targets tumours at both the cellular and genetic levels is required, given the complicated behaviour of tumours and the involvement of several genetic and cellular components involved in tumorigenesis and metastasis. One innovative therapeutic T cell engineering technique that has gained traction is chimeric antigen receptor (CAR) Chimergic Antigen Receptor - T cell thera

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Le Bras, Alexandra. "CAR T therapy affects mouse cognition." Lab Animal 54, no. 6 (2025): 134. https://doi.org/10.1038/s41684-025-01568-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Luo, Liangkui, Xuan Zhou, Lijuan Zhou, et al. "Current state of CAR-T therapy for T-cell malignancies." Therapeutic Advances in Hematology 13 (January 2022): 204062072211430. http://dx.doi.org/10.1177/20406207221143025.

Повний текст джерела

Анотація:

Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteristic of high heterogeneity and poor prognoses. The efficacy of current treatments for this group of diseases is limited. CAR-T therapy is a promising solution to ameliorate the current therapeutic situation. One of the major challenges is that normal T-cells typically share mutual antigens with mali

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Chen, Yi-Ju, Bams Abila, and Yasser Mostafa Kamel. "CAR-T: What Is Next?" Cancers 15, no. 3 (2023): 663. http://dx.doi.org/10.3390/cancers15030663.

Повний текст джерела

Анотація:

The year 2017 was marked by the Food and Drug Administration (FDA) approval of the first two chimeric antigen receptor-T (CAR-T) therapies. The approved indications were for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and for the treatment of patients up to 25 years of age with acute lymphoblastic leukemia (ALL) that is refractory or in a second or later relapse. Since then, extensive research activities have been ongoing globally on different hematologic and solid tumors to assess the safety and efficacy of CAR-T therapy for these diseases. Limitations to CAR

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Hrabovský, Štěpán. "CAR T-cells: hot news in cancer therapy." Vnitřní lékařství 66, no. 7 (2020): 420–24. http://dx.doi.org/10.36290/vnl.2020.121.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Haslauer, Theresa, Richard Greil, Nadja Zaborsky, and Roland Geisberger. "CAR T-Cell Therapy in Hematological Malignancies." International Journal of Molecular Sciences 22, no. 16 (2021): 8996. http://dx.doi.org/10.3390/ijms22168996.

Повний текст джерела

Анотація:

Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hemat

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Padmanjali, Daggupati Sai, Boyina Revathi, and Marri Jalaiah. "Revealing Facts About CAR-T Cell Therapy." ImmunoAnalysis 2 (December 24, 2022): 6. http://dx.doi.org/10.34172/ia.2022.06.

Повний текст джерела

Анотація:

Chimeric antigen receptor (CAR)-T cell therapy is a fast-emerging treatment for several types of cancers and has several applications beyond oncology. It is a new emerging treatment targeting for a broad range of cancers. The objective of this review is to provide the trending information on CAR-T cell therapies, basic principles involved in the CAR-T cell therapy, structure of CAR-T cell, and mainly various clinical applications in the field of oncology as well as beyond oncology, and major side effects of CAR-T cell therapy, methods to overcome the risk factors and to minimize the cost. Alth

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Y, Elshimali. "Chimeric Antigen Receptor T-Cell Therapy (Car T-Cells) in Solid Tumors, Resistance and Success." Bioequivalence & Bioavailability International Journal 6, no. 1 (2022): 1–6. http://dx.doi.org/10.23880/beba-16000163.

Повний текст джерела

Анотація:

CARs are chimeric synthetic antigen receptors that can be introduced into an immune cell to retarget its cytotoxicity toward a specific tumor antigen. CAR T-cells immunotherapy demonstrated significant success in the management of hematologic malignancies. Nevertheless, limited studies are present regarding its efficacy in solid and refractory tumors. It is well known that the major concerns regarding this technique include the risk of relapse and the resistance of tumor cells, in addition to high expenses and limited affordability. Several factors play a crucial role in improving the efficacy

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Eskandar, Kirolos, and Melad Sayh. "CAR-T Cell Therapy: Revolutionizing Cancer Treatment." Indonesian Journal of Cancer Chemoprevention 15, no. 1 (2024): 76. http://dx.doi.org/10.14499/indonesianjcanchemoprev15iss1pp76-86.

Повний текст джерела

Анотація:

CAR-T cell therapy has emerged as a groundbreaking approach in cancer treatment, offering new hope for patients with refractory and relapsed malignancies. This literature review provides a comprehensive overview of the development, applications, and future directions of CAR-T cell therapy. We explore the principles behind CAR-T cell engineering, highlight the clinical successes and challenges in treating hematologic malignancies, and discuss the potential and hurdles in targeting solid tumors. The review also examines the safety profiles, including adverse effects management, and delves into t

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Ajavavarakula, Tatchapon. "CRISPR-edited CAR-T cells: Using CRISPR-Cas9 to Improve CAR-T Therapy." Highlights in Science, Engineering and Technology 14 (September 29, 2022): 355–59. http://dx.doi.org/10.54097/hset.v14i.1846.

Повний текст джерела

Анотація:

One of the cornerstones of cancer immunotherapy, chimeric antigen receptor T cell (CAR-T) immunotherapy is a treatment comprising of T cells transfected with artificial receptors that target a specific tumor antigen, potentiating tumor destruction. Despite the effectiveness of this technique in treating hematopoietic malignancies, efficacy against other cancers leaves much to be desired. CAR-T therapy's anti-tumor effectiveness, safety, and accessibility are hampered by issues such T cell exhaustion, toxicity, and ineffective production techniques. With the advent of CRISPR-Cas9 technology, al

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Ozdemirli, Metin, Thomas M. Loughney, Emre Deniz, et al. "Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy." New England Journal of Medicine 390, no. 22 (2024): 2074–82. http://dx.doi.org/10.1056/nejmoa2401530.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Lyu, Mingzheng. "CAR-T Cell Therapy in Solid Tumor." Highlights in Science, Engineering and Technology 74 (December 29, 2023): 1421–25. http://dx.doi.org/10.54097/srya2x22.

Повний текст джерела

Анотація:

Chimeric antigen receptor (CAR) T cell immunotherapy has gained significant popularity in recent years as a promising approach for cancer treatment. This form of immunotherapy involves the genetic modification of T cells to enable them to recognize and attack cancer cells within the body. Despite the advancements in CAR-T cell therapy and related technologies, several challenges persist in the field of solid tumor research. These challenges include antigen escape, off-target effects, and the complex immune microenvironment. This study aims to evaluate the advantages and drawbacks of CAR-T cell

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Penack, Olaf, and Christian Koenecke. "Complications after CD19+ CAR T-Cell Therapy." Cancers 12, no. 11 (2020): 3445. http://dx.doi.org/10.3390/cancers12113445.

Повний текст джерела

Анотація:

Clinical trials demonstrated that CD19+ chimeric antigen receptor (CAR) T-cells can be highly effective against a number of malignancies. However, the complete risk profile of CAR T-cells could not be defined in the initial trials. Currently, there is emerging evidence derived from post approval studies in CD19+ CAR T-cells demonstrating both short-term and medium-term effects, which were unknown at the time of regulatory approval. Here, we review the incidence and the current management of CD19+ CAR T-cell complications. We highlight frequently occurring events, such as cytokine release syndr

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!